The genomics space is rapidly innovating. The ARK Genomic Revolution Multi-Sector Fund ( ARKG ) makes accessing innovation much easier. For investors, ARKG’s active management and utility are vital because the fund is flexible and able to capitalize on genomics advancements more rapidly than index-based rivals.
The accelerating adoption of digital technologies in emerging economies will open growth opportunities for investors. “With the emergence of COVID-19, we saw an unprecedented step up in the pace of new adoption and integration, as the need to communicate and conduct business digitally became an imperative rather than simply a choice.
Tesla stock is surging on Friday, up 7.6%, and headed toward $900 per share, as it looks to close out an unprecedented 11th trading day higher. In addition to boosting ETFs like the ARK Industrial Innovation ETF (NYSEArca: ARKQ), Tesla stock is up 36% over its 11 sessions of gains, the longest winning streak on record.
It’s now the largest actively managed exchange traded of any variety, and its one of the best-performing ETFs this year, active or passive. The ARK Innovation ETF ( ARKK ) didn’t get here by chance. ARKK is often highlighted for being an early ETF advocate for Tesla ( NASDAQ : TSLA ). The case for Tesla upside remains strong because of continuous advancements in EV. “Electric vehicles may cost about the same as their gas-guzzling brethren in just three or four years — and only get cheaper from there,” reports David Baker for Bloomberg .
Amid an already hectic trading session, as investors contend with larger-than-normal trading volumes due to quadruple witching, the phenomenon when options and…
INTRODUCING 3 NEW MEMBERS OF THE INVESCO QQQ FAMILY
The WisdomTree U.S. Quality Dividend Growth ETF ( DGRW ) focuses on the dividend growth & quality factors and could be uniquely positioned to outperform in a post-vaccine world Positioning For The Re-Opening Rally The news of Pfizer’s potential coronavirus vaccine yielding very encouraging results in the early findings of its clinical trial was more than enough to send investors racing into risk assets betting that a full economic recovery could be on the way.
Instead, DGRW looks at long-term earnings growth expectations as a proxy for a company’s ability to continue paying and growing its dividend over time.
ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing.
“CRISPR’s addressable market in the monogenic disease space could scale to $75B annually with nearly $2T in latent demand from unaddressed populations.